Fyn Kinase Inhibition As a Novel Therapy for Alzheimer's Disease

Overview

Journal Alzheimers Res Ther

Date 2014 Feb 6

PMID 24495408

Citations 90

Authors

Haakon B Nygaard

Christopher H van Dyck

Stephen M Strittmatter

Affiliations

Soon will be listed here.

Abstract

Alzheimer's disease (AD) is a devastating neurodegenerative disorder, afflicting more than one-third of people over the age of 85. While many therapies for AD are in late-stage clinical testing, rational drug design based on distinct signaling pathways in this disorder is only now emerging. Here we review the putative signaling pathway of amyloid-beta (Aβ), by which the tyrosine kinase Fyn is activated via cell surface binding of Aβ oligomers to cellular prion protein. Several lines of evidence implicate Fyn in the pathogenesis of AD, and its interaction with both Aβ and Tau renders Fyn a unique therapeutic target that addresses both of the major pathologic hallmarks of AD. We are currently enrolling patients in a phase Ib study of saracatinib (AZD0530), a small molecule inhibitor with high potency for Src and Fyn, for the treatment of AD. The results of this trial and a planned phase IIa multisite study will provide important data regarding the potential for this therapeutic strategy in AD.

Citing Articles

Identification of novel Kv1.3 channel-interacting proteins using proximity labelling in T-cells.

Kour D, Bowen C, Srivastava U, Nguyen H, Kumari R, Kumar P bioRxiv. 2025; .

PMID: 39868101 PMC: 11760797. DOI: 10.1101/2025.01.16.633279.

Paradoxical attenuation of early amyloid-induced cognitive impairment and synaptic plasticity in an aged APP/Tau bigenic rat model.

Emmerson J, Do Carmo S, Lavagna A, Huang C, Wong T, Martinez-Trujillo J Acta Neuropathol Commun. 2024; 12(1):193.

PMID: 39707506 PMC: 11662582. DOI: 10.1186/s40478-024-01901-0.

How Protein Depletion Balances Thrombosis and Bleeding Risk in the Context of Platelet's Activatory and Negative Signaling.

Montecino-Garrido H, Trostchansky A, Espinosa-Parrilla Y, Palomo I, Fuentes E Int J Mol Sci. 2024; 25(18).

PMID: 39337488 PMC: 11432290. DOI: 10.3390/ijms251810000.

Tyrosine kinases: multifaceted receptors at the intersection of several neurodegenerative disease-associated processes.

Stevenson M, Algarzae N, Moussa C Front Dement. 2024; 3:1458038.

PMID: 39221072 PMC: 11361951. DOI: 10.3389/frdem.2024.1458038.

Single-Nucleus Landscape of Glial Cells and Neurons in Alzheimer's Disease.

Lu M, Li J, Huang Q, Mao D, Yang G, Lan Y Mol Neurobiol. 2024; 62(3):2695-2709.

PMID: 39153159 DOI: 10.1007/s12035-024-04428-6.

References

Kennedy M . Signal-processing machines at the postsynaptic density. Science. 2000; 290(5492):750-4. DOI: 10.1126/science.290.5492.750. View

Luo Y, Hirashima N, Li Y, Alkon D, Sunderland T, Etcheberrigaray R . Physiological levels of beta-amyloid increase tyrosine phosphorylation and cytosolic calcium. Brain Res. 1995; 681(1-2):65-74. DOI: 10.1016/0006-8993(95)00282-u. View

Umemori H, Sato S, Yagi T, Aizawa S, Yamamoto T . Initial events of myelination involve Fyn tyrosine kinase signalling. Nature. 1994; 367(6463):572-6. DOI: 10.1038/367572a0. View

Fury M, Baxi S, Shen R, Kelly K, Lipson B, Carlson D . Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC). Anticancer Res. 2011; 31(1):249-53. PMC: 3705960. View

Yang K, Belrose J, Trepanier C, Lei G, Jackson M, Macdonald J . Fyn, a potential target for Alzheimer's disease. J Alzheimers Dis. 2011; 27(2):243-52. DOI: 10.3233/JAD-2011-110353. View

Larson M, Sherman M, Amar F, Nuvolone M, Schneider J, Bennett D . The complex PrP(c)-Fyn couples human oligomeric Aβ with pathological tau changes in Alzheimer's disease. J Neurosci. 2012; 32(47):16857-71a. PMC: 3568961. DOI: 10.1523/JNEUROSCI.1858-12.2012. View

Roberson E, Halabisky B, Yoo J, Yao J, Chin J, Yan F . Amyloid-β/Fyn-induced synaptic, network, and cognitive impairments depend on tau levels in multiple mouse models of Alzheimer's disease. J Neurosci. 2011; 31(2):700-11. PMC: 3325794. DOI: 10.1523/JNEUROSCI.4152-10.2011. View

Alier K, Ma L, Yang J, Westaway D, Jhamandas J . Aβ inhibition of ionic conductance in mouse basal forebrain neurons is dependent upon the cellular prion protein PrPC. J Neurosci. 2011; 31(45):16292-7. PMC: 6633251. DOI: 10.1523/JNEUROSCI.4367-11.2011. View

Lambert M, Barlow A, Chromy B, Edwards C, Freed R, Liosatos M . Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. Proc Natl Acad Sci U S A. 1998; 95(11):6448-53. PMC: 27787. DOI: 10.1073/pnas.95.11.6448. View

10.

Hennequin L, Allen J, Breed J, Curwen J, Fennell M, Green T . N-(5-chloro-1,3-benzodioxol-4-yl)-7-[2-(4-methylpiperazin-1-yl)ethoxy]-5- (tetrahydro-2H-pyran-4-yloxy)quinazolin-4-amine, a novel, highly selective, orally available, dual-specific c-Src/Abl kinase inhibitor. J Med Chem. 2006; 49(22):6465-88. DOI: 10.1021/jm060434q. View

11.

Reddy K, Smith D, Plow E . Analysis of Fyn function in hemostasis and alphaIIbbeta3-integrin signaling. J Cell Sci. 2008; 121(Pt 10):1641-8. PMC: 3711128. DOI: 10.1242/jcs.014076. View

12.

Sperber B, Engleka M, Gadue P, Peterson A, Stein P, Scherer S . A unique role for Fyn in CNS myelination. J Neurosci. 2001; 21(6):2039-47. PMC: 6762613. View

13.

Selkoe D . Alzheimer's disease is a synaptic failure. Science. 2002; 298(5594):789-91. DOI: 10.1126/science.1074069. View

14.

Freir D, Nicoll A, Klyubin I, Panico S, Mc Donald J, Risse E . Interaction between prion protein and toxic amyloid β assemblies can be therapeutically targeted at multiple sites. Nat Commun. 2011; 2:336. PMC: 3156817. DOI: 10.1038/ncomms1341. View

15.

Resh M . Fyn, a Src family tyrosine kinase. Int J Biochem Cell Biol. 1998; 30(11):1159-62. DOI: 10.1016/s1357-2725(98)00089-2. View

16.

Sicheri F, Kuriyan J . Structures of Src-family tyrosine kinases. Curr Opin Struct Biol. 1998; 7(6):777-85. DOI: 10.1016/s0959-440x(97)80146-7. View

17.

Thomas S, Brugge J . Cellular functions regulated by Src family kinases. Annu Rev Cell Dev Biol. 1997; 13:513-609. DOI: 10.1146/annurev.cellbio.13.1.513. View

18.

Goldsmith J, Hall C, Atkinson T . Identification of an alternatively spliced isoform of the fyn tyrosine kinase. Biochem Biophys Res Commun. 2002; 298(4):501-4. DOI: 10.1016/s0006-291x(02)02510-x. View

19.

Chin J, Palop J, Puolivali J, Massaro C, Bien-Ly N, Gerstein H . Fyn kinase induces synaptic and cognitive impairments in a transgenic mouse model of Alzheimer's disease. J Neurosci. 2005; 25(42):9694-703. PMC: 6725734. DOI: 10.1523/JNEUROSCI.2980-05.2005. View

20.

Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M . Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial. Alzheimers Res Ther. 2011; 3(2):16. PMC: 3226277. DOI: 10.1186/alzrt75. View